Koers CytRx Corporation Other OTC
Aandelen
CYTR
US2328286081
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 644K 592K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -4 mln. -3,68 mln. | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 1,15 mln. 1,05 mln. | Nettoliquiditeiten 2023 | 2,04 mln. 1,87 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,05
x | K/w-verhouding 2023 |
1,91
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,44% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 10-01-22 |
John Caloz
DFI | Director of Finance/CFO | 72 | 01-10-07 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 29-07-21 |
Cary Claiborne
BRD | Director/Board Member | 64 | 27-07-22 |
Joel Caldwell
BRD | Director/Board Member | 69 | 12-07-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,43% | 49,18 mld. | |
+0,74% | 42,11 mld. | |
+50,47% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+13,66% | 26,09 mld. | |
-22,76% | 18,71 mld. | |
+8,25% | 13,26 mld. | |
+32,98% | 12,32 mld. | |
-1,39% | 11,99 mld. |